Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAMM-10 phase 3 trial of belantamab mafodotin + lenalidomide + dexamethasone versus daratumumab + lenalidomide + dexamethasone in transplant-ineligible newly diagnosed multiple myeloma
MOH_2025-06-10_014134Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Jun 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Belantamab mafodotin + lenalidomide + dexamethasone with Daratumumab + lenalidomide + dexamethasone (2 arms). Planned start Jun 2025; status: not yet recruiting.
02
Drugs
belantamab mafodotindaratumumablenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2025-06-10_014134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-06-10_014134.